On 3 November 2006, orphan designation (EU/3/06/413) was granted by the European Commission to Dr Falk Pharma GmbH, Germany, for budesonide (oral use) for the treatment of Graft-versus-Host disease.
Treatment of graft-versus-host disease
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.